| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
Development of targeted agents including sorafenib have been improving the overall survival in metastatic renal cell carcinoma patients. However, most of the patients acquire resistant for targeted agents, and develop cancer death. We defined that LDL counteracts the antitumor effect of sorafenib. Hence we investigated the mechanism.
Adding LDL into renal cancer cell lines, Akt/mTOR pathway was activated; which leads to cell proliferation and anti-cell-death. This mechanism inhibits cell-death by sorafenib and sunitinib.
|
